Post-Transplant Extracorporeal Membrane Oxygenation for Severe Primary Graft Dysfunction to Support the Use of Marginal Donor Hearts.

Severe primary graft dysfunction (PGD) is the leading cause of early postoperative mortality following orthotopic heart transplantation (OHT). Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been used as salvage therapy. This study aimed to evaluate the outcomes in adult OHT recipients who underwent VA-ECMO for severe PGD. We retrospectively reviewed 899 adult (≥18 years) patients who underwent primary OHT at our institution between 1997 and 2017. Recipients treated with VA-ECMO (19, 2.1%) exhibited a higher incidence of previous cardiac surgery ( p = .0220), chronic obstructive pulmonary disease ( p = .0352), and treatment with a calcium channel blocker ( p = .0018) and amiodarone ( p = .0148). Cardiopulmonary bypass ( p = .0410) and aortic cross-clamp times ( p = .0477) were longer in the VA-ECMO cohort and they were more likely to have received postoperative transfusion ( p = .0013); intra-aortic balloon pump (IABP, p < .0001), and reoperation for bleeding or tamponade ( p < .0001). The 30-day, 1-year, and overall survival after transplantation of non-ECMO patients were 95.9, 88.8, and 67.4%, respectively, compared to 73.7, 57.9, and 47.4%, respectively in the ECMO cohort. Fourteen (73.7%) of the ECMO patients were weaned after a median of 7 days following OHT (range: 1-12 days). Following OHT, VA-ECMO may be a useful salvage therapy for severe PGD and can potentially support the usage of marginal donor hearts.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Shudo, Alassar, Wang, Lingala, He, Zhu, Hiesinger, MacArthur, Boyd, Lee, Currie and Woo.)